Intellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPR gene editing therapy for the treatment of ...

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...

Intellia Therapeutics Inc (NTLA) stock saw a modest uptick, ending the day at $9.5 which represents a slight increase of $0.08 or 0.85% from the prior close of $9.42. The stock opened at $9.48 and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Shares of Intellia Therapeutics, Inc. NTLA were down in pre-market trading on Jan. 10 after the company announced a strategic reorganization to prioritize its portfolio of late-stage pipeline ...

Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia ...